[
  {
    "ts": null,
    "headline": "INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?",
    "summary": "Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.",
    "url": "https://finnhub.io/api/news?id=c604b20bad51260bf9856b78885f5ba2bb91920351baebf9cd332b083a709c6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755699480,
      "headline": "INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?",
      "id": 136438113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.",
      "url": "https://finnhub.io/api/news?id=c604b20bad51260bf9856b78885f5ba2bb91920351baebf9cd332b083a709c6b"
    }
  },
  {
    "ts": null,
    "headline": "Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?",
    "summary": "Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=2aac07c8afbb1f89b7b80d93feb6d624a70a3e7ff7597c498827dbef8e2b10b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755694518,
      "headline": "Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?",
      "id": 136450903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=2aac07c8afbb1f89b7b80d93feb6d624a70a3e7ff7597c498827dbef8e2b10b2"
    }
  },
  {
    "ts": null,
    "headline": "Cytokinetics Names Jim Daly to Board of Directors",
    "summary": "SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors. “Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guid",
    "url": "https://finnhub.io/api/news?id=2d1e7a79fd8c23e6d397269af2711d5b3bf26fedd0f929d061cecb807a62edff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755689400,
      "headline": "Cytokinetics Names Jim Daly to Board of Directors",
      "id": 136437612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors. “Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guid",
      "url": "https://finnhub.io/api/news?id=2d1e7a79fd8c23e6d397269af2711d5b3bf26fedd0f929d061cecb807a62edff"
    }
  }
]